ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology

Data from Two Key Studies Highlight Cross‑Reactivity and Broad‑Spectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine Technology 

  • Poster Session 1 – Pratima Kumari, PhD, GeoVax Scientist
    Poster Number: 1050
    Title: “MVA‑vectored multi‑antigen COVID‑19 vaccines induce protective immunity against SARS‑CoV‑2 variants spanning Alpha to Omicron in preclinical animal models.”
    When: June 5, 2025 at 12:00 p.m.
  • Poster Session 2 – Amany Elsharkawy, PhD, Georgia State University Scientist
    Poster Number: 2047
    Title: “GEO‑CM04S1 vaccine candidate maintains potent cross‑reactivity against original SARS‑CoV‑2 B.1 and Omicron subvariant XBB.1.5.”
    When: June 6, 2025 at 7:30 p.m.

“These presentations underscore our commitment to advancing innovative MVA-vaccine vector-based strategies to optimally target the continually evolving SARS-CoV2 virus,” said Mark Newman, PhD, Chief Scientific Officer at GeoVax. “The data we are sharing at the Keystone conference showcase the importance of inducing broadly specific immune responses, specifically T-cell responses to both the Spike and Nucleocapsid viral proteins. We envision use of this type of vaccine in populations where first-generation products have failed to induce optimally efficacious responses, including multiple types of immunocompromised patients.”

GeoVax’s participation at Keystone further demonstrates its leadership in leveraging next‑generation technologies to combat infectious diseases and reinforce preparedness against emerging variants. The event will bring together experts and innovators from across the globe to discuss the latest advancements in the field. For more information on the Keystone Conference, please visit the Keystone Symposia website: https://www.keystonesymposia.org/conferences/conference-listing/meeting/onpage-program/g12025

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Company Contact:
info@geovax.com
678-384-7220 

Investor Relations Contact:
geovax@precisionaq.com
212-698-8696

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.